Keywords
Diabetic nephropathy
Postprandial blood glucose
Submitted : 2023-02-28
Accepted : 2023-03-15
Published : 2023-03-30
Abstract
Objective: To investigate the relationship between postprandial blood glucose (PBG), fasting insulin (FINS), and glycated hemoglobin (HbA1c) levels and early diabetic nephropathy in patients with type 2 diabetes. Methods: 96 cases of type 2 diabetes mellitus treated in our hospital from May 2021 to May 2022 were selected as the research subjects. The patients were divided into two groups according to the urinary albumin excretion rate (UAER), with 53 cases in the type 2 diabetes group (UAER < 30 ?g/min) and 43 cases in the early diabetic nephropathy group (30 ?g/min ? UAER < 300 ?g/min). PBG, FINS, and HbA1c levels were detected in 87 healthy patients. Results: The levels of PBG, FINS, and HbA1c in the early diabetic nephropathy group were higher than those in the control group (P < 0.01) and the type 2 diabetes group (P < 0.01). Conclusion: PBG, FINS, and HbA1c are factors affecting the occurrence of diabetic nephropathy in patients with type 2 diabetes; thus, controlling the levels of PBG, FINS, and HbA1c can effectively prevent the occurrence of diabetic nephropathy in type 2 diabetes mellitus.
References
Zhang Y, Xu M, 2022, The Predictive Value of ApoB/ApoA1 Ratio for Early Diabetic Nephropathy in Patients with Type 2 Diabetes. Medical Theory and Practice, 35(24): 4258–4260.
Zhang R, 2022, Analysis of Risk Factors of Early Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus. Chinese Medical Engineering, 30(02): 25–27.
Guo J, Wei H, Liang Z, et al., 2022, Influencing Factors of Early Diabetic Nephropathy in Patients with Type 2 Diabetes. Chinese Health Engineering, 21(01): 99–100 + 103.
Yang L, Shi W, Zhao L, et al., 2022, Clinical Observation on the Effect of Visceral Fat Area on Early Diabetic Nephropathy in Patients with Type 2 Diabetes. Yunnan Medicine, 43(01): 40–43.
Ding J, Gao W, Huang Z, et al., 2021, Analysis of Related Influencing Factors of Patients with Type 2 Diabetes Developing Early Diabetic Nephropathy. Electronic Journal of Modern Medicine and Health Research, 5(18): 111–113.
Wang B, 2021, Clinical Effect Analysis of Saxagliptin Tablets Combined with Telmisartan Tablets in the Treatment of Early Diabetic Nephropathy in Type 2 Diabetes. Chinese Modern Drug Application, 15(15): 164–166.
Liu S, Wang S, Zuo H, et al., 2021, Diagnostic Value of Cystatin C in Early Nephropathy in Patients with Type 2 Diabetes. Clinical Medicine Research and Practice, 6(03): 36–39.
Cai L, 2020, Application Observation of Neutrophil/Lymphocyte Ratio in Early Diagnosis of Type 2 Diabetic Nephropathy. Chinese Medical Innovation, 17(02): 60–63.
Liu Y, 2019, Correlation Analysis Between Early Diabetic Nephropathy and TCM Constitution in Patients with Type 2 Diabetes Combined with SCH, thesis, Liaoning University of Traditional Chinese Medicine.
Yang S, Wang F, 2019, Study on Related Risk Factors of Type 2 Diabetes Complicated with Early Diabetic Nephropathy. Electronic Journal of Clinical Medicine Literature, 6(08): 26.
Luo Z, 2018, Clinical Exploration of Saxagliptin Combined with Telmisartan on Patients with Type 2 Diabetes and Early Diabetic Nephropathy. Chinese Modern Drug Application, 12(16): 84–86.
Wang L, 2018, Analysis of Related Risk Factors of Type 2 Diabetes Combined with Early Diabetic Nephropathy. Imaging Research and Medical Application, 2(05): 209–211.
Su D, 2018, The Value of Resting Heart Rate in Patients with Type 2 Diabetes in Predicting Early Diabetic Nephropathy. Chinese Medicine Herald, 15(05): 58–61.
Wang H, Wan L, Gao W, et al., 2017, Therapeutic Effect of Saxagliptin Combined with Telmisartan on Patients with Type 2 Diabetes and Early Diabetic Nephropathy. Jiangsu Medicine, 43(06): 446–448.
Zhang N, Gao Z, 2016, Analysis of the Incidence and Risk Factors of Early Diabetic Nephropathy in Patients with Type 2 Diabetes. Journal of Aerospace Medicine, 27(12): 1473–1476.
Niu Y, Zhang J, Wen X, et al., 2021, Clinical Effect of Telmisartan Combined with Calcitriol in the Treatment of Patients with Early Diabetic Nephropathy and Its Effect on Serum Lp(a) and TGF-?1 Levels. Clinical Misdiagnosis and Mistreatment, 34(3): 31–35.